Hereditary Renal Cell Carcinoma — Trials

Hereditary Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

12 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 40%
Top sponsor: Jonsson Comprehensive Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03401788	A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)	active not recruiting	Phase 2	50	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY	4	Apr 13, 2026	clinicaltrials

Data updated 22 days agoSource updated Apr 13, 2026source: clinicaltrials